Wang Maode, Yoshida Daizo, Liu Shouxun, Teramoto Akira
Department of Neurosurgery, The First Hospital, Xi'an Jiaotong University, No.1 Jiankang Road, Xi'an, China.
J Neurooncol. 2005 Mar;72(1):1-9. doi: 10.1007/s11060-004-1392-0.
Malignant glioma invasion into the surrounding brain tissue is still a major problem for any therapeutical methods. Matrix metalloproteinases (MMPs) have been implicated as important factors in this pathological process. In this study, one of the non-steroidal anti-inflammatory drugs (NSAIDs) indomethacin was employed to investigate the effect of inhibition of cell invasion mediated by MMP-2 and MMP-9 in human malignant glioma cell lines, A172, U87MG, U251MG, and U373MG in vitro. MTT assay was firstly examined to determine non-cytotoxic dose range, then gelatin zymography, matrigel invasion assay, migration assay and MMP-2 activity assay for 24 h exposure in indomethacin were employed to assess the inhibitory effect of indomethacin. MTT assay revealed that dose with 0, 50, and 500 microM/ml were non-cytotoxic. Zymography demonstrated: (a) expression of MMP-2 and MMP-9 activity was downregulated along with elevated dose of indomethacin. (b) MMP-2 activity that changed from pro-MMP-2 to active form of MMP-2 in supernatants of cell lines could not be inhibited by indomethacin. Invasion assay disclosed that the number of invading cells through the matrigel were significantly decreased in a dose dependent manner. Migration assay indicated indomethacin did not affect cells migration. MMP-2 activity assay showed the total and active MMP-2 secretion was suppressed by 500 microM/ml of indomethacin. Our present study is the first report on inhibitive effect of indomethacin mediated by MMP-2 and MMP-9 in invasion assay of glioma cell lines. The current study suggested that non-cytotoxic level of indomethacin was able to reduce the cell invasion of malignant gliomas mediated by MMP-2 and MMP-9, but it did not affected on cell motility. It also lowered down the activity of MMP-2 and MMP-9, and could reduce of MMP-2 secretion of cell lines. Thus, high concentration of indomethacin within non-cytotoxic dose might offer a new therapeutic strategy to impair cell invasion of gliomas.
恶性胶质瘤侵入周围脑组织仍然是任何治疗方法面临的主要问题。基质金属蛋白酶(MMPs)被认为是这一病理过程中的重要因素。在本研究中,使用非甾体抗炎药(NSAIDs)之一的吲哚美辛来研究其对人恶性胶质瘤细胞系A172、U87MG、U251MG和U373MG中由MMP - 2和MMP - 9介导的细胞侵袭的抑制作用。首先通过MTT法检测以确定无细胞毒性剂量范围,然后采用明胶酶谱法、基质胶侵袭试验、迁移试验以及吲哚美辛作用24小时后的MMP - 2活性试验来评估吲哚美辛的抑制作用。MTT试验表明,0、50和500微摩尔/毫升的剂量无细胞毒性。酶谱分析显示:(a)随着吲哚美辛剂量增加,MMP - 2和MMP - 9活性的表达下调。(b)细胞系上清液中从无活性MMP - 2转变为活性形式MMP - 2的MMP - 2活性不受吲哚美辛抑制。侵袭试验表明,穿过基质胶的侵袭细胞数量呈剂量依赖性显著减少。迁移试验表明吲哚美辛不影响细胞迁移。MMP - 2活性试验显示,500微摩尔/毫升的吲哚美辛可抑制总MMP - 2和活性MMP - 2的分泌。我们目前的研究是关于吲哚美辛在胶质瘤细胞系侵袭试验中由MMP - 2和MMP - 9介导的抑制作用的首次报道。当前研究表明,无细胞毒性水平的吲哚美辛能够减少由MMP - 2和MMP - 9介导的恶性胶质瘤细胞侵袭,但不影响细胞运动性。它还降低了MMP - 2和MMP - 9的活性,并可减少细胞系MMP - 2的分泌。因此,无细胞毒性剂量的高浓度吲哚美辛可能为损害胶质瘤细胞侵袭提供一种新治疗策略。